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Background: Not all clinical trials are pub-
lished, which may distort the evidence that is
available in the literature. We studied the publica-
tion rate of a cohort of clinical trials and identi-
fied factors associated with publication and non-
publication of results.
Methods: We analysed the protocols of ran-
domized clinical trials of drug interventions sub-
mitted to the research ethics committee of Uni-
versity Hospital (Inselspital) Bern, Switzerland
from 1988 to 1998. We identified full articles
published up to 2006 by searching the Cochrane
CENTRAL database (issue 02/2006) and by con-
tacting investigators. We analyzed factors associ-
ated with the publication of trials using descrip-
tive statistics and logistic regression models.
Results: 451 study protocols and 375 corre-
sponding articles were analyzed. 233 protocols
 resulted in at least one publication, a publication
rate of 52%. A total of 366 (81%) trials were com-
mercially funded, 47 (10%) had non-commercial
funding. 346 trials (77%) were multi-centre stud-
ies and 272 of these (79%) were international col-
laborations. In the adjusted logistic regression
model non-commercial funding (Odds Ratio
[OR] 2.42, 95% CI 1.14–5.17), multi-centre sta-
tus (OR 2.09, 95% CI 1.03–4.24), international
collaboration (OR 1.87, 95% CI 0.99–3.55) and a
sample size above the median of 236 participants
(OR 2.04, 95% CI 1.23–3.39) were associated
with full publication.
Conclusions: In this cohort of applications to
an ethics committee in Switzerland, only about
half of clinical drug trials were published. Large
multi-centre trials with non-commercial funding
were more likely to be published than other trials,
but most trials were funded by industry. 
Key words: clinical trials; drug trials; full publica-
tion; study protocols; reporting biases; longitudinal
study 
Summary
Patients, health professionals and policy mak-
ers need access to all the available evidence on the
effects of health care interventions in order to
make appropriate decisions. It has long been
recognised that only a proportion of research
projects ultimately reaches the stage of full publi-
cation in a peer-reviewed journal. In 1979, Rosen-
thal described the gloomy scenario where jour-
nals are filled with spurious results that happened
to reach statistical significance, whilst researcher
archives are filled with the many non-significant
study results [1]. The selective publication of
“positive”, statistically significant results, called
the “file drawer problem” by Rosenthal, is better
known as publication bias [2].
In practice, the dissemination of research
findings follows a continuum from informal pre-
sentations, conference poster or oral presentation
with or without a published abstract to letters,
short reports and original articles in a journal in-
dexed in the main bibliographic databases. Only
original articles contain sufficient detailed infor-
mation to allow critical appraisal and decision-
making. Conference abstracts are difficult to lo-
cate as most appear in conference proceedings
and these are typically not included in biblio-
graphic databases.
The earliest stage of detailed study documen-
tation is when study protocols are being sub -
mitted to research ethics committees or funding
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agencies. Such protocols are increasingly being
recognised as a valuable source of information for
research on the dissemination of research [3].
Several studies have followed research proposals
approved by research ethics committees or insti-
tutional review boards [4–8].
We set out to investigate the publication or
non-publication of clinical trials based on a co-
hort of protocols submitted to a research ethics
committee of a university hospital in Switzerland.
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Methods
Cohort of study protocols
We were granted access to the paper files of all study
protocols submitted from 1988 to 1998 to the research
ethics committee of University Hospital Bern (Inselspi-
tal), Switzerland. These files included submitted study
protocols, amendments and related correspondence in-
cluding committee decisions and communications on
conduct and completion of studies. Our study was sub-
mitted to and approved by the Cantonal authorities re-
sponsible for data protection issues. 
We classified all submitted studies by study design
using pre-defined criteria. The present analysis was re-
stricted to protocols of randomised trials of drug inter-
ventions (drug trials). A drug trial was defined as a study
of one or more drugs in humans, independent of the
route of administration. Studies that did not compare at
least two different drugs or one drug with a placebo or no
treatment were excluded. For example, we excluded stud-
ies comparing different doses or routes of administration
of the same drug.
Identification of publications
Electronic searches
We systematically searched the CENTRAL database
(Cochrane Library, issue 02/2006) to identify full publica-
tions with a potential link to the included protocols.
CENTRAL is a comprehensive database of controlled
trials maintained by the Cochrane Collaboration [9]. It
includes trials published in journals not indexed in MED-
LINE, EMBASE or other bibliographic databases and in
languages other than English [10]. We defined a full pub-
lication as an article published in a medical journal pro-
viding detailed information on methods and results.
For each protocol, we developed a search strategy,
based on information from the protocol, for example the
study name or acronym, condition studied and the names
of the applicant. Potentially eligible publications were re-
trieved and further examined. Publications were included
if they reported results from an eligible study.
Survey of applicants
Between April and July 2006 we sent a standardized
questionnaire to the investigators of all included proto-
cols. The questionnaire asked about the current status of
the project (ongoing or completed) and provided a list of
publications identified. We asked the applicants to con-
firm that the publications corresponded to the study pro-
tocol in question and to provide references of any addi-
tional publications. We checked addresses of non-respon-
ders by electronic searches and attempted to contact
them by letter, e-mail or telephone. For protocols sub-
mitted in the last two years of observation (1997 and
1998) with no publications and no response from investi-
gators, we searched online trial registries and the internet
to determine the status of the study. These searches iden-
tified no ongoing studies. 
Data collection and definitions
We established two databases, one for data extracted
from the protocols and another for data extracted from
related publications. Databases were linked by unique
identifier numbers. A standardised data abstraction form
was used to extract data on study characteristics, includ-
ing the experimental (and control) drug, study design,
sample size, source of funding and pre-specified out-
comes from all eligible protocols. Data were extracted by
one investigator and cross-checked by a second; discrep-
ancies were resolved by consensus. 
Commercial funding was defined as any financial
support or provision of study materials by industry. For
commercially funded trials, we recorded if the sponsor
was involved in the planning of the study, data manage-
ment or analysis. We assumed such involvement if a  
co-author of the study protocol was affiliated with a 
company. Non-commercial funding included financial or
other support by public funding agencies, public or pri-
vate foundations (if not clearly linked to a private com-
pany) or research funds of hospital or university entities.
A study with at least one collaborating centre outside
Switzerland was classified as an international study. Some
protocols indicated a range (rather than a single value) for
the planned sample size and duration of follow up. In
these cases we used the smallest value. 
Statistical analysis
We used standard descriptive statistics. The publica-
tion rate was calculated as the proportion of protocols
with at least one related full article. We used multiple lo-
gistic regression models with full publication as the de-
pendent variable and characteristics of protocols and pub-
lications as independent variables. We used STATA ver-
sion 9.2 (STATA Corporation, Austin/Texas, USA) for all
analyses. Results of regression models were expressed as
odds ratios (ORs) with 95% CIs. 
Results
Inclusions of protocols and publications
A total of 1698 protocols were submitted to
the research ethics committee from 1988 to 1998
(fig. 1). We excluded 119 entries because the files
could not be located or did not include a complete
study protocol and a further 1048 protocols of
studies other than randomized drug trials. We
were left with 531 eligible protocols submitted by
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225 investigators. For 44 protocols the project
status was documented as “stopped prematurely”.
We contacted the applicants of the  remaining 487
protocols. At the time of submission of the proto-
col most were affiliated with the University Hos-
pital of Bern. We obtained responses for 348 of
487 protocols (response rate 71%). Eighty of 531
studies (15%) had not been completed at the time
of the survey for various reasons (fig. 1): 57 trials
(including the 44 trials mentioned above) were
stopped prematurely, 16 trials never started, 5 trials
were not approved by the ethics committee and
two trials were ongoing. The reasons for stopping
the 57 trials included insufficient enrolment of
participants in 22, negative results or lack of 
efficacy in 9, adverse events in 7, loss of interest 
by investigators or sponsors in 7, other reasons in
10 and unknown reasons in two trials.
Our sample thus comprised 451 protocols of
completed drug trials. We identified 326 publica-
tions through literature searches and 49 addi-
tional publications through our survey, for a total
of 375 publications. These related to 233 study
protocols. The publication rate was therefore
52% (233/451). The median number of publica-
tions per protocol was 1 (range 1 to 14). Sixty-
three (14%) protocols had more than one related
publication.
Characteristics of protocols
The characteristics of studies that resulted in
a publication and of studies that remained unpub-
lished are summarised in table 1. The 451 trials
were conducted in various fields of academic
medicine and dentistry; most commonly in oncol-
ogy (n = 67, 15%), cardiology (n = 44, 10%) and
infectious diseases (n = 42, 9%). The number of
submitted protocols per year increased from 24 in
1989 (the first complete year included) to 69 in
1998. 
Most trials were of a parallel design (n = 418,
93%). Among these 108 (26%) had three or more
treatment arms and nine (2%) used a factorial
 design. Thirty-three trials (7%) were cross-over
trials. The planned sample size was given in 447
(99%) protocols and ranged from 4 to 15 000 par-
ticipants (median 236 participants). The planned
duration of enrolment was specified in 220 (49%)
protocols and ranged from 1 to 108 months (me-
dian 12 months). 
One hundred and five (23%) studies were
 single-centre studies and 346 (77%) were multi-
centre studies. Of the latter, 272 (79%) included
international centres, 66 (19%) national collabo-
rations and for eight (2%) the collaborating cen-
tres were not described in the protocol. Of the
272 international studies, seven (3%) were led by
a Swiss study centre and 240 (88%) by a study
centre abroad. The leading study centre was un-
clear in 25 (9%) protocols. 
The source of funding was reported in 393
(87%) studies and was unclear in the remaining 58
(13%) studies. Commercial funding was reported
in 366 (81%) protocols. In 42 of these studies (11%)
the commercial sponsor provided study drugs or
other material but was not involved in the conduct
of the trial. Non-commercial funding was reported
for 47 protocols (10%) and in 20 (4%) protocols
S W I S S  M E D  W K LY 2 0 0 8 ; 13 8 ( 13 – 14 ) : 19 7 – 2 0 3  ·  w w w. s m w. ch
119 excluded for administrative reason
(protocol incomplete or not found)
1698
protocols
submitted to REC
1048 excluded for ineligible study design:
  451 drug trials with no control group
  348 trials of other interventions (eg surgery)
      8 non-randomised drug trials
  175 observational studies
    59 laboratory studies
      7 not classifiable
80 not completed as of 06/2006:
57 stopped prematurely
16 never started
  5 rejected
  2 ongoing
531
protocols of
randomized drug
trials
451
protocols included
Figure 1
Flowchart of included
protocols.
All Published Unpublished
(n = 451) (n = 233) (n = 218)
Median year of 1995 (88–98) 1995 (88–98) 1994 (89–98)
protocol submission 
(range)
Clinical specialty
Oncology 67 (15%) 45 (19%) 22 (10%)
Cardiology 44 (10%) 32 (14%) 12 (6%)
Infectious diseases 42 (9%) 20 (9%) 22 (10%)
Gastroenterology 35 (8%) 12 (5%) 23 (11%)
Neurology 29 (6%) 18 (8%) 11 (5%)
Psychiatry 23 (5%) 10 (4%) 13 (6%)
Dentistry 20 (4%) 5 (2%) 15 (7%)
Dermatology 20 (4%) 5 (2%) 15 (7%)
Miscellaneous 171 (39%) 86 (37%) 85 (38%)
Type of study
Parallel group trial 418 (93%) 213 (91%) 205 (94%)
Cross over trial 33 (7%) 20 (9%) 13 (6%)
Planned sample size 236 300 180 
(median, range) (4–15,000) (6–15,000) (4–4,800)
Number of centres
1 105 (23%) 51 (22%) 54 (25%)
>1 346 (77%) 182 (78%) 164 (75%)
International 
collaboration
Yes 272 (60%) 157 (67%) 115 (53%)
No 171 (38%) 75 (32%) 96 (44%)
Unclear 8 (2%) 1 (<1%) 7 (3%)
Source of funding
Commercial 346 (77%) 167 (72%) 179 (82%)
Non-commercial 27 (6%) 19 (8%) 8 (4%)
Both 20 (4%) 15 (6%) 5 (2%)
Unclear or not 58 (13%) 32 (14%) 26 (12%)
mentioned
Table 1
Characteristics 
of published and 
unpublished studies.
REC = research ethics
committee
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both commercial and non-commercial funding
sources were mentioned. There was variation in the
rate of commercial funding across specialities,
ranging from 42 studies (63%) in oncology to 
21 studies (91%) in psychiatry.
Factors associated with publication 
In the unadjusted logistic regression models
the probability of publication decreased if the study
was commercially funded (OR 0.6) (table 2). It in-
creased with non-commercial funding (OR 2.7), 
if the planned sample size was above the median
(OR 2.1) and if the study was international (OR 1.7).
In the adjusted model there were little changes in
the point estimates except for multi-centre status,
which was associated with the probability of publi-
cation in the adjusted model (OR 2.1) but not in the
unadjusted analysis (OR 0.9). 
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Unadjusted OR Adjusted OR 
(95% confidence interval)*
Non-commercial funding versus all other funding 2.7 2.4 (1.1–5.2)
Commercial funding versus all other funding 0.6 0.7 (0.4–1.3)
Large study versus small study** 2.1 2.0 (1.2–3.4)
Multi-centre study versus single-centre study 0.9 2.1 (1.0–4.2)
International versus national study 1.7 1.9 (1.0–3.6)
* Adjusted for all 5 listed variables
** Large studies have sample size above / small studies below the median sample size of all studies (n = 236).
Table 2
Probability of publi-
cation according to
study characteristics.
Discussion
Summary of results
Only about half of the randomized drug trials
approved by an ethics committee in Switzerland
were published during a follow up period that
ranged from seven to over 17 years after approval
of the protocol. The publication of trials was asso-
ciated with several study characteristics, including
source of funding, study size, and international and
multi-centre status. About four out of five studies
were sponsored by industry and in most of these tri-
als the company was directly involved in the con-
duct of the trial. 
Findings in context with other studies
In a bibliographic study of 519 trials indexed in
the PubMed database [11], about three quarters
were of parallel group design, 72% were single-
centre studies and 44% were partly or fully com-
mercially funded. The median sample size was 52.
In our study, more trials were of parallel-group de-
sign and commercially funded and fewer trials were
single-centre studies. The median sample size in
our study was larger. These differences may be 
explained by the different selection criteria: 
all of the PubMed-indexed trials were published (by
definition), whereas only 52% of our trials reached
publication. Also, we restricted our sample to drug
trials, whereas only 76% of the PubMed-indexed
trials examined drug interventions.
We found commercial funding in 81% of the
studies included. In a high percentage (70%) the
commercial sponsor was involved in the conduct of
the study, for example in the design, data manage-
ment or analysis. In other cohorts of study proto-
cols submitted to ethic committees the percentage
of commercial funding ranged from 1% to 89% 
[4–8]. This wide range may be due to differences 
in the studies examined, different definitions of 
“commercial funding” or different study periods.
Clearly, commercial funding is more important 
for clinical trials than for other types of studies [6].
Baltimore Oxford Sydney  France Spain Bern
(Dickersin 1992) [5] (Easterbrook (Stern 1997) (Decullier (Pich 2003) (this study)
1991) [6] [8] 2005) [4] [7]
Medical School Public Health
Period of REC approval 1980 1980 1984–87 1979–88 1994 1997 1988–98
End of follow-up 1988 1988 1990 1992 2002 2001 2006
Number 342 172 285 321 501 123 451 
of proposals (100%) (100%) (100%) (100%) (100%) (100%) (100%)
Full publication 230 104 138 189 190 38 233
(67%) (61%) (49%) (59%) (38%) (31%) (52%)
REC = research ethics committee 
Table 3 
Overview of previous studies of the publication of research proposals submitted to research ethics committees.
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It is well known that many trials remain un-
published after completion of data collection and
analysis. Only about half of abstracts of studies pre-
sented at conferences are later published in full
[12]. Six studies of proposals submitted to ethics
committees in Oxford [6], Sydney [8], the Johns
Hopkins School of Medicine and School of Hy-
giene and Public Health in Baltimore [5] and to na-
tional ethics committees in France [4] and Spain [7]
found rates of publication that ranged from 31% to
67%, with higher rates in the USA, England and
Australia than in non-Anglophone countries (table
3). In our study the publication rate was 52%. The
previous studies did not combine surveys of appli-
cants with electronic searches and included studies
other than drug trials. Our results are therefore not
directly comparable to those from the earlier studies.
Reasons for non-publication
We still lack a full understanding of the reasons
for the non-publication of clinical trials. In a review
of studies following scientific projects after meet-
ing presentations, von Elm and colleagues found
that lack of time was the most commonly men-
tioned barrier to publication, but researchers also
mentioned negative results as an important reason
[13]. Indeed, the selective publication of ‘positive’,
statistically significant results is well documented.
In studies of proposals submitted to ethics com-
mittees (table 3) of trials funded by the National 
Institutes of Health [14], trials submitted to licens-
ing authorities [15], trials in HIV medicine [16] and
analyses of trial registries [17], publication was
more likely if effects were large and statistically sig-
nificant. Figure 2 shows a meta-analytic summary
of five ethics committee cohorts (the study done by
Pich et al. [7] did not provide sufficient informa-
tion on publication bias to be included). The prob-
ability of publication was 2.6 times greater if results
were statistically significant (p <0.05).
We did not examine publication bias. Ascer-
taining the results of unpublished studies that were
completed many years ago is difficult and time-
consuming and this was not feasible within the
framework of this study. Clearly, this is a limitation
of our study, also because the statistical significance
of results may both be related to the probability of
publication and other factors of  interest, for exam-
ple study size and the source of funding. The na-
ture of the results may thus act as a confounding
variable with respect to other factors of interest. Of
note, previous studies of proposals approved by
ethics committees or institutional review boards [5,
6] found only small effects for sample size in analy-
ses adjusted for statistical significance – in contrast
to the present analysis. In these studies external
funding was associated with increased publication
rates even after adjusting for statistical significance,
although results were heterogeneous, possibly be-
cause no distinction was made between commer-
cial and non-commercial sources of funding. 
Strengths and limitations
We analyzed a large and unselected sample of
trial protocols submitted to a University research
ethics committee over a period of eleven years.
Since most trials were international, our results
are not only applicable to our local research envi-
ronment but to similar settings of clinical re-
search abroad. We used a comprehensive litera-
ture search and achieved a response rate of 71%
in our survey of applicants. Nevertheless, we may
have missed some publications. As mentioned
above, we could not examine publication bias.
Many of the studies date back more than 15 years
and many were international collaborations with
a co-ordinating centre outside of Switzerland. We
found that in some cases the Swiss investigators
participating in international studies did not
know whether the study had been published. To
obtain reliable information on the results of un-
published studies, it would be necessary not only
to interview the Swiss investigators: sponsors,
principal investigators or contract research orga -
nisations would probably also need to be con-
tacted.
We restricted our study to drug trials. Conse-
quently, some research fields will be underrepre-
sented in our sample (for example surgery or in-
terventional radiology). We did not use the phase
I to III classification scheme for trials because it
was not used consistently in the included proto-
cols. Almost a decade has elapsed since submis-
sion of the most recent protocols included in our
study. The rate of publication and quality and
characteristics of protocols and publications may
have changed since then, especially in the light of
recent initiatives for the registration of clinical
trials [18, 19]. This may limit the application of
our findings to current practice and illustrates the
dilemma faced by this and many other longitudi-
nal studies: including more recent protocols
would leave insufficient time for studies to be
completed and results to be published [12]. In our
sample, we had to exclude only two studies that
were ongoing in 2006.
Implications 
The high percentage of commercially funded
trials must be a matter of concern. Associations be-
tween the source of funding and the conclusion of
research articles have been reported repeatedly
[20–23]. If funded by for-profit organisations, the
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Combined
Sydney
Oxford
Medical School 
Public Health
Baltimore
France
2.6 (2.0 to 3.4)
Odds Ratio 
0.1 0.5 1 2 10
Publication less likely if p<0.05 Publication more likely if p<0.05
Figure 2
Probability of publi-
cation and statistical
significance of results
(p <0.05): Random
 effects meta-analysis
of five follow-up
studies of protocols
approved by ethics
committees.
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conclusions in randomised trials recommended the
experimental drug as the drug of choice five times
more often than with other funding, even after ad-
justment for the size of the treatment effect [24].
There is also evidence that the tobacco and
telecommunication industries influence the results
of research they funded [25–28]. Possible mecha-
nisms include influence on the design of the study
[29], choice of exposures [29, 30], outcomes [31–
33], statistical methods [34] and investigators, as
well as selective publication of outcomes [31–33]
and studies [12].
In our study the probability of publication was
higher if funding was from a non-commercial
agency and tended to be reduced with commercial
funding. In three cohorts of proposals submitted to
ethics committees industry-independent funding
by government agencies was significantly associ-
ated with publication [5, 6, 8] whereas in two co-
horts, pharmaceutical industry sponsored studies
were less likely to be published [5, 6]. A possible ex-
planation is that the pharmaceutical industry tends
to discourage the publication of negative studies
that it has funded. At least one such example is well
documented. A manuscript reporting on a trial
comparing the bioequivalence of generic and
brand levothyroxine products [35, 36], which had
failed to produce the results the sponsor hoped for,
was withdrawn because the company took legal ac-
tion against the university and the  investigators.
This resulted in a delay in publication of about
seven years. Twenty percent of life-science faculty
members in the United States  reported that they
had experienced delays in publication of their work
and  reasons for not publishing included “to delay
the dissemination of undesired results” [37]. Delays
in publication were  associated with involvement in
commercialisation and academic-industry research
relationship.
Independently of the source of funding, au-
thors may often not submit studies with negative
findings because they anticipate rejection by jour-
nal editors. Interestingly, empirical evidence indi-
cates that selective submission of papers reporting
statistically significant results is more important
than acceptance or rejection of studies based on
their results by journals [5, 6]. Studies of lower
methodological quality are more likely to produce
“positive” results [38] and may therefore be more
likely to be published. We did not collect informa-
tion on the possible submission (and rejection) of
unpublished studies, nor did we attempt to assess
the quality of studies. 
The selective reporting of trials may introduce
bias in reviews and meta-analyses of the available
evidence [17, 34, 39–42], which again may affect
conclusions and misguide policy and future re-
search. The implication is that investigators and
sponsors have the ethical obligation [43] to publish
results independent of the nature of these results,
or make them publicly available through other
means [44], for example on the internet. The In-
ternational Committee of Medical Journal Editors
(ICMJE) argues that “patients who volunteer to
participate in clinical trials deserve to know that
their contribution to improving human health will
be available to inform health-care decisions” [18].
More than a decade ago, the underreporting of
study results was called “a form of scientific mis-
conduct” [45]. Considerable progress has been
made, thanks to the initiative led by the World
Health Organization, to register all clinical trials.
However, the views of the different stakeholders
concerning the content of these registries differ
[46–48].
In conclusion, this large cohort of drug trials
approved by an ethics committee in Switzerland
showed that only about half of the trials were pub-
lished. Among the factors influencing the proba-
bility of publication, the influence of the source of
funding is of particular concern. Our findings sup-
port the need for compulsory trial registration as
well as public funding streams for industry-inde-
pendent clinical trials research.
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the Canton of Bern, its former president Professor Jürg
Hodler, Charles Senessie, Nicola Low, Claire Graber, She-
lagh Redmond, Marcel Zwahlen, Gerd Antes and Martin
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different stages of this study and to the investigators who
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